Pharma IQ announces 5th Biobanking Conference to be held in San Francisco

Pharma IQ, a division of IQPC, announces its 5th Biobanking Conference, to be held August 22 to 24, 2011 in San Francisco, CA. Bringing together experts from across the biomedical research field, the conference addresses the latest advancements in the biobanking sphere, and includes sessions with industry experts on a variety of ethical, privacy, regulatory, legal and profitability issues.

Due to an ever evolving regulatory environment, the biobanking community has not yet reached a consensus on best practices. Privacy practices and ethical issues, including informed consent, are in the spotlight. In a recent interview with Pharma IQ, Kieran O'Doherty, Assistant Professor at the University of Guelph, noted, "When the biobank is first constructed and when research participants are enrolled… often, the researchers don't know what kind of studies are going to be conducted with the samples. So the idea of informed consent just can't be used in the same way." New ways of protecting research participants are needed for the context of biobanking. In the interview, Assistant Professor O'Doherty explores where informed consent fails in the context of biobanking, and new ways of protecting research participants.

For the purposes of addressing these ethical and privacy issues and other issues of great importance for those in the biomedical research field, the 5th IQPC Biobanking Conference will bring together leading industry experts to inform on:

  • How informed consent and privacy practices, policy and governance practice affect biobanking related research and development
  • Understanding evolving regulations and standards as they develop into actual laws
  • Best practices and recommendations in the evaluation and prioritization for research tissue banking
  • Conducting research to support evidence-based best practices
  • Strategic planning and gaining competitive funding for biobank expansion
  • Accelerating genomic studies and maximizing biobanking resources
Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    IQPC Ltd. (2019, June 20). Pharma IQ announces 5th Biobanking Conference to be held in San Francisco. News-Medical. Retrieved on November 27, 2024 from https://www.news-medical.net/news/20110610/Pharma-IQ-announces-5th-Biobanking-Conference-to-be-held-in-San-Francisco.aspx.

  • MLA

    IQPC Ltd. "Pharma IQ announces 5th Biobanking Conference to be held in San Francisco". News-Medical. 27 November 2024. <https://www.news-medical.net/news/20110610/Pharma-IQ-announces-5th-Biobanking-Conference-to-be-held-in-San-Francisco.aspx>.

  • Chicago

    IQPC Ltd. "Pharma IQ announces 5th Biobanking Conference to be held in San Francisco". News-Medical. https://www.news-medical.net/news/20110610/Pharma-IQ-announces-5th-Biobanking-Conference-to-be-held-in-San-Francisco.aspx. (accessed November 27, 2024).

  • Harvard

    IQPC Ltd. 2019. Pharma IQ announces 5th Biobanking Conference to be held in San Francisco. News-Medical, viewed 27 November 2024, https://www.news-medical.net/news/20110610/Pharma-IQ-announces-5th-Biobanking-Conference-to-be-held-in-San-Francisco.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
National Pharmacovigilance Programme to increase awareness about benefits of adverse event reporting